Vivos Inc. (RDGL)
OTCMKTS
· Delayed Price · Currency is USD
0.1255
+0.0066 (5.55%)
Apr 25, 2025, 4:00 PM EDT
Vivos Revenue
In the year 2024, Vivos had annual revenue of $28.00K with 43.56% growth. Vivos had revenue of $5.00K in the quarter ending December 31, 2024.
Revenue
28.00K
Revenue Growth
+43.56%
P/S Ratio
2,032.45
Revenue / Employee
28.00K
Employees
1
Market Cap
56.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
Dec 31, 2020 | 7.00K | -2.50K | -26.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Vivos News
- 4 days ago - Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 - GlobeNewsWire
- 12 days ago - Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 months ago - Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide - GlobeNewsWire
- 4 months ago - Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial - GlobeNewsWire
- 6 months ago - Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - GlobeNewsWire
- 9 months ago - Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA - GlobeNewsWire
- 10 months ago - Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials - GlobeNewsWire
- 1 year ago - Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation - GlobeNewsWire